In a recent publication in Current Drug Research Reviews, researchers conducted a study to assess and compare evidence-based clinical safety, therapeutic potential, and importance (outcomes) of several biosimilars with their references in conjunction with clinical uses in chronic diseases.

For this study, researchers conducted a thorough systemic literature review of more than 100 articles involving medicinally important drugs whose bio-similarity works optimally, and safety-efficacy parameters have been investigated. This review’s primary focus was the assessment of biosimilar usage, approval, and safety-efficacy aspects.

The authors indicated that for this systemic review, “It can be stated that the majority of biosimilars are clinically and statistically equivalent to their originators. As biosimilars have good safety-efficacy aspects with lower prices, their utilization can be more encouraged, which was already done by the FDA with the establishment of a public online database entitled ‘Purple Book,’ which includes all information regarding biological drugs.”

Based on their findings, the authors concluded that across all the accumulated clinical trials and studies, the extensive usage of high-grade biosimilars in clinical practice could be via altering, exchanging, or switching, with appropriate clinical monitoring and pharmacovigilance to expand patient accessibility to modern medicines, as it provides comparable efficacy and safety parameters.

The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.